Rewriting the BioPharma Rule Book

Danaher Chief Science Officer Jose-Carlos Gutierrez-Ramos explores how the biopharma rule book has been rewritten by the pandemic and what to expect from the future of genomic medicines in this exclusive new article for Pharmaceutical Executive magazine…